IP Group eyes further value growth as cash realisations top £85m

IP Group PLC (LSE:IPO) CEO Greg Smith spoke with Proactive's Stephen Gunnion about a strong start to 2026, with NAV per share reaching around 117p and cash proceeds topping £85 million year to date. Smith discussed progress in Pfizer’s obesity programmes, including the berobenatide and amylin combination moving into Phase 2b, alongside further positive data from Pfizer’s lead Phase 3 programme. He also highlighted the wider portfolio, with companies raising more than £540 million of third-party capital in the first half across areas including quantum computing, AI, healthtech and cleantech. IP Group has now generated more than £150 million of realisations since the start of 2025 towards its £250 million target by the end of 2027. Smith also discussed the group’s expanding private capital platform and the potential catalysts across the portfolio over the next 12 to 18 months. Visit Proactive’s YouTube channel for more interviews and market updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #IPGroup #IPGroupPLC #GregSmith #InterimResults #Investing #UKInvesting #TechnologyInvesting #DeepTech #HealthTech #CleanTech #QuantumComputing #ArtificialIntelligence #AIInfrastructure #Pfizer #ObesityTreatment #OxfordQuantumCircuits #QuantumMotion #Oxa #PortfolioCompanies #GrowthInvesting #ProactiveInvestors #Proactive